Neoadjuvant Chemotherapy Use in Breast Cancer is Greatest in Excellent Responders: Triple-Negative and HER2+ Subtypes

Brittany L. Murphy, Courtney N. Day, Tanya L. Hoskin, Elizabeth B. Habermann, Judy C. Boughey

Research output: Contribution to journalArticlepeer-review

37 Scopus citations

Fingerprint Dive into the research topics of 'Neoadjuvant Chemotherapy Use in Breast Cancer is Greatest in Excellent Responders: Triple-Negative and HER2+ Subtypes'. Together they form a unique fingerprint.

Medicine & Life Sciences